(Q39426629)

11 September 2017

title

Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab (English)

1 reference

11 September 2017

Zi-Zhen Xu

1

1 reference

11 September 2017

Zu-Guang Xia

2

1 reference

11 September 2017

Ai-Hua Wang

3

1 reference

11 September 2017

Wen-Fang Wang

4

1 reference

11 September 2017

Zhi-Yin Liu

5

1 reference

11 September 2017

Li-Yun Chen

6

1 reference

11 September 2017

Jun-Min Li

7

1 reference

11 September 2017

publication date

2 May 2013

1 reference

11 September 2017

1 reference

11 September 2017

volume

92

1 reference

11 September 2017

issue

10

1 reference

11 September 2017

page(s)

1351-1358

1 reference

Diagnosis and treatment of diffuse large B-cell lymphoma

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

PI3K/Akt/mTOR pathway as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

Relapsed/refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

AKT/PKB signaling: navigating downstream

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1770-9

10.1007/S00277-013-1770-9

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference